Ticlopidine Hydrochloride

Name: Ticlopidine Hydrochloride

Ticlopidine Hydrochloride ticlopidine hydrochloride dosage
Ticlopidine Hydrochloride mg
Ticlopidine Hydrochloride dosage
Ticlopidine Hydrochloride drug
Ticlopidine Hydrochloride effects of
Ticlopidine Hydrochloride tablet

Ticlopidine Hydrochloride Dosage and Administration

General

Prevention of Coronary Artery Stent Thrombosis

Initiate therapy after successful stent implantation.1 46 71

Administration

Oral Administration

Administer orally with food to maximize GI absorption and tolerance.1 2 71

Dosage

Available as ticlopidine hydrochloride; dosage expressed in terms of the salt.1 71

Adults

Prevention of Thrombotic Stroke Oral

250 mg twice daily.1 71 Has been continued for at least up to 5.8 years in some patients.1 2 71

Prevention of Coronary Artery Stent Thrombosis Oral

Manufacturer recommends 250 mg twice daily, beginning after stent implantation and continuing for up to 30 days in conjunction with antiplatelet dosages of aspirin.1 46 71

If ticlopidine is used in combination with aspirin following drug-eluting stent (DES) implantation, combined therapy with ticlopidine and aspirin must be continued for ≥12 months to minimize the risk of potentially catastrophic stent thrombosis.70 (See Compliance with Therapy in Patients with Drug-eluting Stents under Cautions.)

Special Populations

Hepatic Impairment

No specific dosage recommendations at this time;1 71 contraindicated in patients with severe hepatic impairment.1 71 (See Hepatic Impairment under Cautions.)

Renal Impairment

Reduce dosage or discontinue therapy if hemorrhagic or hematopoietic complications occur.1 71

Geriatric Patients

No specific dosage recommendations at this time.1 71

Interactions for Ticlopidine Hydrochloride

Drugs Metabolized by Hepatic Microsomal Enzymes

Possible increased plasma half-life of concomitantly administered drugs metabolized by hepatic microsomal enzymes; dosage adjustments may be required when initiating or discontinuing ticlopidine therapy.1 71

Specific Drugs

Drug	Interaction	Comments
Antacids	Decreased plasma ticlopidine concentrations1 71
Anticoagulants	Additive effects1 71	Manufacturer recommends discontinuing anticoagulant therapy prior to initiating ticlopidine1 71
Aspirin, other NSAIAs	Additive effect on platelet aggregation1 71	Use with caution in patients who have lesions with a propensity to bleed (e.g., peptic ulcers)1 71 (see Conditions Predisposing to Bleeding under Cautions) Safety of concomitant use of ticlopidine and aspirin beyond 30 days not established;1 46 71 long-term concomitant use not recommended1
Digoxin	Slight decrease in plasma digoxin concentrations1 71	Little or no change in digoxin efficacy expected1 71
Phenobarbital	No inhibition of platelet aggregation effects of ticlopidine1 71
Phenytoin	Increased plasma phenytoin concentrations with associated somnolence and lethargy reported1 71	Cautious use recommended; monitor plasma phenytoin concentrations1 71
Propranolol	Potential for altered protein binding of propranolol1 71	Cautious use recommended1 71
Theophylline	Decreased elimination half-life and total plasma clearance of theophylline1 71
Thrombolytic agents	Additive effects1 71	Manufacturer recommends discontinuing of thrombolytic agents prior to initiating ticlopidine1 71